Jean Stéphenne
Biomedical Sciences
Tigenix
Netherlands
Biography
Jean Stéphenne was, until April 2012, member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chairman and President of GSK Biologicals in Wavre, Belgium, which he built into a world leader in vaccines. He currently serves as Chairman of BESIX, Vesalius Biocapital, Nanocyl, Bepharbel and BioWin, and as board member of BNP Paribas Fortis, Groupe Bruxelles Lambert (GBL), OncoDNA, Theravectys and Ronveaux. Previously, Mr. Stéphenne served as board member of Auguria Residential Real Estate Fund, which is currently in liquidation, VBO/FEB and Welbio.
Research Interest
Jean Stéphenne was, until April 2012, member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chairman and President of GSK Biologicals in Wavre, Belgium, which he built into a world leader in vaccines. He currently serves as Chairman of BESIX, Vesalius Biocapital, Nanocyl, Bepharbel and BioWin, and as board member of BNP Paribas Fortis, Groupe Bruxelles Lambert (GBL), OncoDNA, Theravectys and Ronveaux. Previously, Mr. Stéphenne served as board member of Auguria Residential Real Estate Fund, which is currently in liquidation, VBO/FEB and Welbio.
